secwatch.observer — SEC 8-K summary
======================================

Issuer:     CASTLE BIOSCIENCES INC (CSTL)
CIK:        0001447362
Form:       8-K
Filed at:   2021-08-09T23:59:59+00:00
Accession:  0001447362-21-000197
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Castle Biosciences Q2 revenue $22.8M (+79% YoY); raises FY2021 guidance to $89-93M
--------------------------------------------------------------------------------

- Revenue $22.8M, up 79% YoY; adjusted revenue $22.9M, up 120% YoY excluding prior-period adjustments.
- DecisionDx-Melanoma test reports up 70% YoY to 5,128; total dermatology test volume 6,539.
- Full-year 2021 revenue guidance raised to $89-93M from prior $80-83M.
- Acquired Myriad myPath Laboratory for $33M in May, adding myPath Melanoma test.
- Cash at $368M; operating cash flow -$6.4M due to acquisition and Medicare advance recoupment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447362/000144736221000197/0001447362-21-000197-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447362/000144736221000197/cstl-20210809.htm
  HTML page:      https://secwatch.observer/filing/0001447362-21-000197

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer